Literature DB >> 32391658

[Management of COVID-19: the Zhejiang experience].

Kaijin Xu1,2, Hongliu Cai1, Yihong Shen1, Qin Ni1,2, Yu Chen1, Shaohua Hu1, Jianping Li1, Huafen Wang1, Liang Yu1,2, He Huang1, Yunqing Qiu1, Guoqing Wei1, Qiang Fang1, Jianying Zhou1, Jifang Sheng1,2, Tingbo Liang1, Lanjuan Li1,2.   

Abstract

The current epidemic situation of coronavirus disease 2019 (COVID-19) still remained severe. As the National Clinical Research Center for Infectious Diseases, the First Affiliated Hospital of Zhejiang University School of Medicine is the primary medical care center for COVID-19 in Zhejiang province. Based on the present expert consensus carried out by National Health Commission and National Administration of Traditional Chinese Medicine, our team summarized and established an effective treatment strategy centered on "Four-Anti and Two-Balance" for clinical practice. The "Four-Anti and Two-Balance" strategy included antivirus, anti-shock, anti-hyoxemia, anti-secondary infection, and maintaining of water, electrolyte and acid base balance and microecological balance. Meanwhile, integrated multidisciplinary personalized treatment was recommended to improve therapeutic effect. The importance of early viralogical detection, dynamic monitoring of inflammatory indexes and chest radiograph was emphasized in clinical decision-making. Sputum was observed with the highest positive rate of RT-PCR results. Viral nucleic acids could be detected in 10%patients' blood samples at acute period and 50%of patients had positive RT-PCR results in their feces. We also isolated alive viral strains from feces, indicating potential infectiousness of feces.Dynamic cytokine detection was necessary to timely identifying cytokine storms and application of artificial liver blood purification system. The "Four-Anti and Two-Balance" strategy effectively increased cure rate and reduced mortality. Early antiviral treatment could alleviate disease severity and prevent illness progression, and we found lopinavir/ritonavir combined with abidol showed antiviral effects in COVID-19. Shock and hypoxemia were usually caused by cytokine storms. The artificial liver blood purification system could rapidly remove inflammatory mediators and block cytokine storm.Moreover, it also favored the balance of fluid, electrolyte and acid-base and thus improved treatment efficacy in critical illness. For cases of severe illness, early and also short period of moderate glucocorticoid was supported. Patients with oxygenation index below 200 mmHg should be transferred to intensive medical center. Conservative oxygen therapy was preferred and noninvasive ventilation was not recommended. Patients with mechanical ventilation should be strictly supervised with cluster ventilator-associated pneumonia prevention strategies. Antimicrobial prophylaxis was not recommended except for patients with long course of disease, repeated fever and elevated procalcitonin (PCT), meanwhile secondary fungal infection should be concerned.Some patients with COVID-19 showed intestinal microbial dysbiosis with decreased probiotics such as Lactobacillus and Bifidobacterium, so nutritional and gastrointestinal function should be assessed for all patients.Nutritional support and application of prebiotics or probiotics were suggested to regulate the balance of intestinal microbiota and reduce the risk of secondary infection due to bacterial translocation. Anxiety and fear were common in patients with COVID-19. Therefore,we established dynamic assessment and warning for psychological crisis. We also integrated Chinese medicine in treatment to promote disease rehabilitation through classification methods of traditional Chinese medicine. We optimized nursing process for severe patients to promote their rehabilitation. It remained unclear about viral clearance pattern after the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. Therefore, two weeks' quarantine for discharged patients was required and a regular following up was also needed.The Zhejiang experience and suggestions have been implemented in our center and achieved good results. However, since COVID-19 was a newly emerging disease, more work was warranted to improve strategies of prevention, diagnosis and treatment for COVID-19.

Entities:  

Mesh:

Year:  2020        PMID: 32391658      PMCID: PMC8800711          DOI: 10.3785/j.issn.1008-9292.2020.02.02

Source DB:  PubMed          Journal:  Zhejiang Da Xue Xue Bao Yi Xue Ban        ISSN: 1008-9292


  4 in total

1.  Evaluation of plasma exchange and continuous veno-venous hemofiltration for the treatment of severe avian influenza A (H7N9): a cohort study.

Authors:  Xiaoli Liu; Yimin Zhang; Xiaowei Xu; Weibo Du; Kunkai Su; Chunxia Zhu; Yuemei Chen; Shuiying Lei; Shufa Zheng; Jianwen Jiang; Shigui Yang; Jing Guo; Li Shao; Qian Yang; Jiajia Chen; Lanjuan Li
Journal:  Ther Apher Dial       Date:  2014-11-03       Impact factor: 1.762

2.  Clinical findings in 111 cases of influenza A (H7N9) virus infection.

Authors:  Hai-Nv Gao; Hong-Zhou Lu; Bin Cao; Bin Du; Hong Shang; Jian-He Gan; Shui-Hua Lu; Yi-Da Yang; Qiang Fang; Yin-Zhong Shen; Xiu-Ming Xi; Qin Gu; Xian-Mei Zhou; Hong-Ping Qu; Zheng Yan; Fang-Ming Li; Wei Zhao; Zhan-Cheng Gao; Guang-Fa Wang; Ling-Xiang Ruan; Wei-Hong Wang; Jun Ye; Hui-Fang Cao; Xing-Wang Li; Wen-Hong Zhang; Xu-Chen Fang; Jian He; Wei-Feng Liang; Juan Xie; Mei Zeng; Xian-Zheng Wu; Jun Li; Qi Xia; Zhao-Chen Jin; Qi Chen; Chao Tang; Zhi-Yong Zhang; Bao-Min Hou; Zhi-Xian Feng; Ji-Fang Sheng; Nan-Shan Zhong; Lan-Juan Li
Journal:  N Engl J Med       Date:  2013-05-22       Impact factor: 91.245

3.  Human infections with the emerging avian influenza A H7N9 virus from wet market poultry: clinical analysis and characterisation of viral genome.

Authors:  Yu Chen; Weifeng Liang; Shigui Yang; Nanping Wu; Hainv Gao; Jifang Sheng; Hangping Yao; Jianer Wo; Qiang Fang; Dawei Cui; Yongcheng Li; Xing Yao; Yuntao Zhang; Haibo Wu; Shufa Zheng; Hongyan Diao; Shichang Xia; Yanjun Zhang; Kwok-Hung Chan; Hoi-Wah Tsoi; Jade Lee-Lee Teng; Wenjun Song; Pui Wang; Siu-Ying Lau; Min Zheng; Jasper Fuk-Woo Chan; Kelvin Kai-Wang To; Honglin Chen; Lanjuan Li; Kwok-Yung Yuen
Journal:  Lancet       Date:  2013-04-25       Impact factor: 79.321

4.  A novel coronavirus outbreak of global health concern.

Authors:  Chen Wang; Peter W Horby; Frederick G Hayden; George F Gao
Journal:  Lancet       Date:  2020-01-24       Impact factor: 79.321

  4 in total
  43 in total

Review 1.  Altered gut microbiota patterns in COVID-19: Markers for inflammation and disease severity.

Authors:  Chiranjib Chakraborty; Ashish Ranjan Sharma; Manojit Bhattacharya; Kuldeep Dhama; Sang-Soo Lee
Journal:  World J Gastroenterol       Date:  2022-07-07       Impact factor: 5.374

2.  Culturing Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) for Diagnosis and Genome Sequencing.

Authors:  Zhiqi Zeng; Hua Guo; Liping Chen; Zhengshi Lin; Wenda Guan; Yutao Wang; Haiming Jiang; Xiao Wu; Yong Yin; Zelong Gao; Canxiong Chen; Zifeng Yang
Journal:  Lab Med       Date:  2022-06-17

3.  Anxiety and fear of COVID-19 among nursing students during the COVID-19 pandemic: A descriptive correlation study.

Authors:  Nilgun Kuru Alici; Ebru Ozturk Copur
Journal:  Perspect Psychiatr Care       Date:  2021-05-20       Impact factor: 2.223

Review 4.  Mechanisms of Nausea and Vomiting: Current Knowledge and Recent Advances in Intracellular Emetic Signaling Systems.

Authors:  Weixia Zhong; Omar Shahbaz; Garrett Teskey; Abrianna Beever; Nala Kachour; Vishwanath Venketaraman; Nissar A Darmani
Journal:  Int J Mol Sci       Date:  2021-05-28       Impact factor: 5.923

Review 5.  Liver injury in COVID-19: Detection, pathogenesis, and treatment.

Authors:  Yue Cai; Li-Ping Ye; Ya-Qi Song; Xin-Li Mao; Li Wang; Yan-Zhi Jiang; Wei-Tao Que; Shao-Wei Li
Journal:  World J Gastroenterol       Date:  2021-06-14       Impact factor: 5.742

Review 6.  Nutrition and immunity: lessons for COVID-19.

Authors:  Philip C Calder
Journal:  Nutr Diabetes       Date:  2021-06-23       Impact factor: 5.097

7.  The human microbiome and COVID-19: A systematic review.

Authors:  Shinya Yamamoto; Makoto Saito; Azumi Tamura; Diki Prawisuda; Taketoshi Mizutani; Hiroshi Yotsuyanagi
Journal:  PLoS One       Date:  2021-06-23       Impact factor: 3.752

8.  COVID-19 associated nervous system manifestations.

Authors:  Fatima Khatoon; Kartikay Prasad; Vijay Kumar
Journal:  Sleep Med       Date:  2021-07-09       Impact factor: 4.842

Review 9.  Nutrition and immunity: lessons for COVID-19.

Authors:  Philip C Calder
Journal:  Eur J Clin Nutr       Date:  2021-06-23       Impact factor: 4.884

10.  Oxygen therapy strategies and techniques to treat hypoxia in COVID-19 patients.

Authors:  B Jiang; H Wei
Journal:  Eur Rev Med Pharmacol Sci       Date:  2020-10       Impact factor: 3.784

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.